Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Newly Diagnosed Multiple Myeloma

Share this content:
Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Ne
Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Ne

CME

Program Description:

The combination of carfilzomib, lenalidomide, and low-dose dexamethasone has been shown to be highly active in patients with newly diagnosed multiple myeloma and provides rapid and deep responses, according to a presentation at the 2012 Annual Meeting of the American Society of Clinical Oncology. Extended treatment was well tolerated and resulted in improved depth of response, with a high stringent complete response rate and a significant proportion of patients without evidence of minimal residual disease.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with multiple myeloma.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Compare the efficacy and safety of regimens that contain an immunomodulatory agent and a proteasome inhibitor as initial treatment of newly diagnosed multiple myeloma (MM).

  • Assess the response rates for pomalidomide in combination with low-dose dexamethasone in refractory MM patients unresponsive to transplantation.

Click Next to begin the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs